SCYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
SCYNEXIS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$3.66−0.01 (-0.27%)
Close on Oct 19, 2026
- Market cap
- $43.28M
- P/E (TTM)
- –
- Dividend yield
- –
SCYNEXIS INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2014 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License Agreement Revenue | $19.16M | $3.75M | $139.10M | $103.00K | $12.05M | $0 | $100.00K | $300.00K | $300.00K | – | 93.0% | +411.4% |
| Product Revenue, Net | $1.44M | $0 | $1.04M | $4.99M | $1.11M | $0 | – | – | – | – | 7.0% | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2014 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | – | – | – | – | – | $16.42M | – | – |
| Other non-US | – | – | – | – | – | – | – | – | – | $1.37M | – | – |
| Europe | – | – | – | – | – | – | – | – | – | $1.24M | – | – |
From the segment and revenue-disaggregation notes of Scynexis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.